



## **BioOutsource launches flagship Reverse Signalling Apoptosis Bioassay**

*Presents webinar on improving speed to market for Biosimilars*

GLASGOW, Scotland and BOSTON, Mass –24 March , 2014 – [BioOutsource](#) Ltd. (“BioOutsource”), a global leader in biologics contract testing and BioSimilar characterisation for the biopharmaceutical industry, today announced the launch of the flagship Reverse Signalling Apoptosis Bioassay, adding to the extensive range of characterisation services offered by the company. The assay is a critical method, required by the regulators for licensure of [Humira](#) and [Remicade](#) BioSimilars.

[The Reverse Signalling Apoptosis bioassay](#) replicates a critical component of TNF-Alpha biology whereby membrane bound TNF-Alpha acts as a receptor, mediating a negative feedback system following binding by the TNF2 receptor. This results in cytokine suppression and the induction of apoptosis in TNF-Alpha producing cells, thereby dampening the elevated immune response.

BioOutsource CSO, Dr Daniel Galbraith commented; “We are delighted to be the first to bring the Reverse Signalling Apoptosis Assay to market. It completes our extensive range of characterisation testing capabilities and ensures BioOutsource now support the full biological characterisation of Humira and Remicade BioSimilars.”

In addition, BioOutsource also announced that Dr. Galbraith will shortly present a webinar on [How Biological Characterisation is improving speed to market for BioSimilars](#).

Dr. Galbraith commented “The webinar will present how the biological characterisation of BioSimilar Monoclonal Antibodies plays a critical role in the development pathway for Biosimilars. I am looking forward to presenting our extensive experience in this area and engaging with thought leaders in the industry in the Q&A section”. The [webinar](#) is being hosted in partnership with Business Review Webinars on 27<sup>th</sup> March 2014 at 3pm GMT.

BioOutsource has also announced that it will shortly be exhibiting at CHI’s [Biotherapeutics Analytical Summit](#) in Baltimore, USA on 24-28<sup>th</sup> March 2014, followed by Informa’s, [BioProcessing International European Summit](#) in Prague, Czech Republic on 2-3<sup>rd</sup> April 2014.

For more information on our upcoming conferences and events please follow this [link](#).

## **About BioOutsource Ltd**

BioOutsource provides contract testing services to the biopharmaceutical industry. Our core offering includes a comprehensive range of services to support the testing of Biologics, Vaccines & BioSimilaris throughout their development. We possess an unparalleled combination of commercial, regulatory and technical knowledge that enables us to truly stand out as the industry's increasingly preferred testing partner. We understand the importance of our service to support our client's critical testing requirements and as a result, continually strive to provide a world class service globally.

## **Contacts**

### **For BioOutsource:**

Gemma Fulton  
Sales & Marketing Associate  
BioOutsource, Ltd.  
+ 44 (0) 141 948 1291  
[gfulton@biooutsource.com](mailto:gfulton@biooutsource.com)